268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading
268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading
First, we discuss why Wall Street was less than convinced by Biogen's attempt to assuage concerns about its credibility.... Read more
27 Jul 2023
•
36mins
267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford
267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford
Neil Kumar, CEO of BridgeBio, joins us to talk about how his small company came to develop what could be a big drug — an... Read more
20 Jul 2023
•
35mins
Similar Podcasts
The Long Run with Luke Timmerman
BioCentury This Week
a16z Podcast
First Opinion Podcast
Odd Lots
Planet Money
Goldman Sachs Exchanges
Inside the Strategy Room
FYI - For Your Innovation
Slate Money
KFF Health News' 'What the Health?'
Business Breakdowns
Freakonomics Radio
Tradeoffs
HBR IdeaCast
266: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads
266: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads
Our colleague Megan Molteni joins us to explain the evolving science suggesting products like Wegovy are less weight los... Read more
13 Jul 2023
•
32mins
265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market
265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market
Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight... Read more
29 Jun 2023
•
35mins
Most Popular Podcasts
The Joe Rogan Experience
TED Talks Daily
The Tim Ferriss Show
The Daily
Stuff You Should Know
Oprah's SuperSoul Conversations
Armchair Expert with Dax Shepard
264: Messy PBM conflicts, debatable vaccines, & the future of flu season
264: Messy PBM conflicts, debatable vaccines, & the future of flu season
Our colleague Bob Herman joins us to explain his year-long investigation into some brazen conflicts of interest in the w... Read more
22 Jun 2023
•
36mins
263: Biogen's messy board, Laronde's data problem, & the downside of a boom
263: Biogen's messy board, Laronde's data problem, & the downside of a boom
Our colleague Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde Therapeutics, bille... Read more
15 Jun 2023
•
39mins
262: Merck v. USA, the best of ASCO, and Leqembi at the FDA
262: Merck v. USA, the best of ASCO, and Leqembi at the FDA
STAT Washington correspondent Rachel Cohrs joins us to explain Merck's lawsuit against the federal government and why th... Read more
8 Jun 2023
•
29mins
261: Fake medical devices, real cancer drugs, & curious Ozempic effects
261: Fake medical devices, real cancer drugs, & curious Ozempic effects
Our colleague Lizzy Lawrence joins us to explain the shocking story of a medical device company that sold fake implants ... Read more
1 Jun 2023
•
31mins
260: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA
260: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA
As hospitals and health care companies are racing to implement large language models like ChatGPT into their businesses,... Read more
25 May 2023
•
31mins
259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround
259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround
Jared Holz, biotech strategist at Mizuho Securities, joins us to explain why federal regulators are suing to block Amgen... Read more
18 May 2023
•
40mins
